Previous Close | 29.00 |
Open | 29.46 |
Bid | 29.73 x 200 |
Ask | 29.92 x 100 |
Day's Range | 29.39 - 30.36 |
52 Week Range | 25.60 - 77.60 |
Volume | |
Avg. Volume | 479,048 |
Market Cap | 736.454M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.42 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 57.11 |
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.
Disc's light sensitivity drug succeeded in a test Monday, but a large placebo response confounded the results. The biotech stock plummeted.